A pelvic examination may provide information about the uterus, ovaries, and surrounding tissues. It can sometimes identify a mass or areas of tenderness.
However, a normal examination does not always exclude ovarian cancer, especially when disease is small or located in a position that is difficult to assess.
Similarly, finding an ovarian mass does not automatically mean cancer is present. Many ovarian masses are benign, and their appearance must be interpreted alongside other clinical findings.
The clinician should explain the purpose of the examination and obtain consent before proceeding.
A person may ask questions, request clarification, or discuss any concerns about discomfort, privacy, or the examination process.
Step 3: Ultrasound Imaging
Ultrasound is an important tool in the evaluation of suspected ovarian abnormalities.
A transabdominal ultrasound uses a probe on the abdomen, while a transvaginal ultrasound uses a specialized probe placed in the vagina to obtain more detailed images of the pelvic organs.
The appropriate method depends on the clinical situation, patient preference, and whether the examination is suitable.
Ultrasound can help determine whether an ovarian mass is present, its approximate size, whether it contains fluid or solid tissue, and whether certain features appear more or less concerning.
Some cysts have a simple fluid-filled appearance and are likely to be benign. Other masses may have complex structures, solid components, or other features that require additional evaluation.
Imaging findings are not interpreted in isolation. Age, menopausal status, symptoms, and other test results all influence the assessment.
An ultrasound cannot always determine with certainty whether a mass is cancerous. Some benign and malignant lesions have overlapping appearances.
Further tests or specialist review may therefore be necessary.
Step 4: CA-125 Blood Testing
CA-125 is a protein that can be measured in the blood. It is often used as part of the assessment when ovarian cancer is suspected.
Levels may be elevated in some people with ovarian cancer, but the test has important limitations.
CA-125 can also rise in noncancerous conditions, including endometriosis, menstruation, pelvic inflammatory disease, pregnancy, and certain other illnesses.
Conversely, some people with ovarian cancer have CA-125 levels that are not elevated, particularly in certain early-stage cases or tumor types.
This means that CA-125 cannot independently confirm or exclude ovarian cancer.
Its usefulness depends on the clinical context and the way results are combined with other findings.
For example, a clinician may interpret a CA-125 result alongside ultrasound findings and menopausal status when assessing an ovarian mass.
The test is also sometimes used to monitor treatment response or follow disease activity after diagnosis.
However, routine CA-125 testing has not been shown to reduce ovarian cancer deaths when used alone to screen asymptomatic people at average risk. It should not be presented as a simple annual blood test that reliably detects ovarian cancer before symptoms appear.
Step 5: Additional Imaging and Specialist Referral
If the initial assessment raises concern, further imaging may be recommended.
Computed tomography, commonly called CT, can help assess the abdomen and pelvis, including the extent of a suspected cancer and whether other structures may be involved.
Magnetic resonance imaging, or MRI, may provide additional information about certain pelvic masses when ultrasound findings are inconclusive.
The choice depends on the question the clinician is trying to answer.
When ovarian cancer is suspected, referral to a gynecologic oncologist may be appropriate. These specialists have expertise in cancers of the female reproductive system and can help plan further investigations and treatment.
Early involvement of a gynecologic oncologist is particularly important when imaging or other findings suggest a significant possibility of malignancy, because specialist surgical planning can influence treatment outcomes.
Not every person with an ovarian cyst needs this type of referral. Many cysts are benign and can be monitored or treated according to their characteristics.
The purpose of further investigation is to distinguish between conditions that can be managed conservatively and those requiring more specialized care.
Step 6: Confirming the Diagnosis
A definitive diagnosis generally requires examination of tissue by a pathologist.
In many cases, tissue is obtained during surgery. The procedure depends on the suspected cancer type, the extent of disease, and the patient's overall condition.
For some patients, treatment may begin with surgery intended to remove the tumor and obtain diagnostic tissue. In others, a biopsy may be performed before systemic treatment, particularly when the disease appears advanced or surgery is not the most appropriate initial approach.
The precise method is determined by the treating team.
Once tissue is available, pathologists examine the cells under a microscope and may use additional laboratory techniques to identify the tumor type.
The diagnosis can then guide decisions about surgery, chemotherapy, targeted therapy, and other treatments.
Doctors may also recommend genetic testing or tumor testing, because inherited and acquired genetic changes can influence treatment choices and family counseling.
The treatment plan depends on the cancer's type, stage, molecular characteristics, and the patient's preferences and general health.
Why Routine Screening Is Different From Diagnostic Testing
One of the most persistent misconceptions about ovarian cancer is that every person should undergo regular ultrasound scans or CA-125 blood tests to detect the disease early.
For people at average risk who have no symptoms, major medical guidance does not recommend routine ovarian cancer screening using these tests because the benefits have not been shown to outweigh the potential harms.
False-positive results can lead to unnecessary follow-up procedures, anxiety, and sometimes surgery for conditions that are not cancerous.
At the same time, the absence of a recommended routine screening test does not mean that symptoms should be ignored.
Screening and diagnosis serve different purposes.
If someone develops persistent abdominal swelling, pelvic pain, early fullness, or unexplained urinary changes, a clinician can evaluate those symptoms and decide whether testing is warranted.
People with known inherited high-risk variants may require a different management plan involving genetic counseling, individualized